跳至主要内容
临床试验/NCT01998685
NCT01998685已完成不适用

Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy

Regina Elena Cancer Institute1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
Rate of rate of prothrombotic markers and Vascular Endothelial Growth Factor (VEGF) variation

研究概览

简要总结

This study aims to assess if different anesthetic techniques can affect coagulant factors in patients with prostate cancer undergoing elective laparoscopic radical prostatectomy (LRP).

详细描述

The utility of anti-thrombotic prophylaxis in cancer patients undergoing laparoscopic radical prostatectomy (LRP) is still controversial. Moreover, different anaesthetic techniques could modify coagulant factors. Thus, in this study we will be to investigate the variations of pro- and anti-coagulant and fibrinolytic factors in two established types of anaesthesia in patients with prostate cancer undergoing elective LRP.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • newly diagnosed cancer of the prostate
  • histological Gleason score evaluation.

排除标准

  • metabolic equivalent task < 4
  • no pre-operative pharmacological thromboprophylaxis and/or anti-coagulant therapy
  • history of abnormal bleeding, or abnormal coagulant factors
  • sepsis within the last 2 weeks
  • previous new adjuvant treatments (chemo, hormone, and radiotherapy)
  • non-steroid , anti-inflammatory and statins drugs for at least 2 wks before surgery
  • venous or arterial thromboembolism within the last 3 months, peripheral venous disease
  • neurological disease with extremity paresis
  • chronic liver disease
  • pre-operative haemoglobin concentration < 9 mg dl-1
  • prolonged duration of surgery (>3 hrs)
  • peri-operative blood transfusion
  • not adequate material for laboratory testing

研究组 & 干预措施

Balanced (BAL) anaesthesia

Experimental

In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.

干预措施: Midazolam (Drug)

Balanced (BAL) anaesthesia

Experimental

In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.

干预措施: Fentanyl (Drug)

Balanced (BAL) anaesthesia

Experimental

In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.

干预措施: Sevoflurane (Drug)

Totally Intravenous Anesthesia (TIVA-TCI)

Active Comparator

In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.

干预措施: Propofol (Drug)

Totally Intravenous Anesthesia (TIVA-TCI)

Active Comparator

In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.

干预措施: remifentanyl (Drug)

结局指标

主要结局

Rate of rate of prothrombotic markers and Vascular Endothelial Growth Factor (VEGF) variation

时间窗: 24 hours

次要结局

  • Free-desease survivall(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ester Forastiere

chief

Regina Elena Cancer Institute

研究点 (1)

Loading locations...

相似试验